164 related articles for article (PubMed ID: 37125227)
1. Successful Treatment of Persistent
Hsu AJ; Simner PJ; Bergman Y; Mathers AJ; Tamma PD
Open Forum Infect Dis; 2023 Apr; 10(4):ofad174. PubMed ID: 37125227
[No Abstract] [Full Text] [Related]
2. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
Petraitis V; Petraitiene R; Kavaliauskas P; Naing E; Garcia A; Georgiades BN; Echols R; Bonomo RA; Yamano Y; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0061822. PubMed ID: 36154614
[TBL] [Abstract][Full Text] [Related]
3. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Vialichka A; Jurkovic M; Wu T; Shajee A; Lee M; Patel S; Mendes RE; Wenzler E
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571820
[TBL] [Abstract][Full Text] [Related]
4. A Combination of Trimethoprim-sulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against
Ismail N; Zam Z; Hassan SA; Rahman ZA
Malays J Med Sci; 2017 Mar; 24(2):21-27. PubMed ID: 28894400
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
Junco SJ; Bowman MC; Turner RB
Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
[TBL] [Abstract][Full Text] [Related]
6.
Nakamura R; Oota M; Matsumoto S; Sato T; Yamano Y
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526491
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Sader HS; Duncan LR; Arends SJR; Carvalhaes CG; Castanheira M
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900683
[TBL] [Abstract][Full Text] [Related]
8. Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate.
Alsuhaibani M; Aljarbou A; Althawadi S; Alsweed A; Al-Hajjar S
Antimicrob Resist Infect Control; 2021 Jan; 10(1):19. PubMed ID: 33482916
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
10. Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.
Wu RX; Yu CM; Hsu ST; Wang CH
J Microbiol Immunol Infect; 2022 Feb; 55(1):107-113. PubMed ID: 33500210
[TBL] [Abstract][Full Text] [Related]
11. Severe cellulitis/myositis caused by Stenotrophomonas maltophilia.
Downhour NP; Petersen EA; Krueger TS; Tangella KV; Nix DE
Ann Pharmacother; 2002 Jan; 36(1):63-6. PubMed ID: 11816260
[TBL] [Abstract][Full Text] [Related]
12. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for
Sarzynski SH; Warner S; Sun J; Matsouaka R; Dekker JP; Babiker A; Li W; Lai YL; Danner RL; Fowler VG; Kadri SS
Open Forum Infect Dis; 2022 Feb; 9(2):ofab644. PubMed ID: 35097154
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017.
Wang L; Zhou W; Cao Y; Yang C; Liu H; Chen T; Chen L
Medicine (Baltimore); 2020 Feb; 99(8):e19250. PubMed ID: 32080131
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological Trends and Resistance Associated with
Gajdács M; Urbán E
Diseases; 2019 May; 7(2):. PubMed ID: 31159258
[No Abstract] [Full Text] [Related]
15. Antibiotic Susceptibility and Minimum Inhibitory Concentration for
Ho MM; Sun MH; Wu WC; Lai CC; Yeh LK; Hwang YS; Hsiao CH; Chen KJ
Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358112
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
[TBL] [Abstract][Full Text] [Related]
17. Treatment approaches for severe Stenotrophomonas maltophilia infections.
Mojica MF; Bonomo RA; van Duin D
Curr Opin Infect Dis; 2023 Dec; 36(6):572-584. PubMed ID: 37846568
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of trimethoprim/sulfamethoxazole resistance genes among Stenotrophomonas maltophilia clinical isolates in Egypt.
Elsheredy A; Elsheikh A; Ghazal A; Shawky S
Acta Microbiol Immunol Hung; 2021 Sep; ():. PubMed ID: 34546967
[TBL] [Abstract][Full Text] [Related]
19. Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole.
Yilmaz M; Celik AF; Mert A
J Infect Chemother; 2007 Apr; 13(2):122-3. PubMed ID: 17458682
[TBL] [Abstract][Full Text] [Related]
20.
Hamdi AM; Fida M; Abu Saleh OM; Beam E
Open Forum Infect Dis; 2020 Jan; 7(1):ofaa008. PubMed ID: 32016126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
